Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer: Multicentric randomized FONICAP trial report

Authors:
  • FSFranco Salvati
    Franco Salvati
  • RRRiccardo Rosso
    Riccardo Rosso
  • MPMaria Cristina Pennucci
    Maria Cristina Pennucci
  • GMGabriella Lucia Mariani
    Gabriella Lucia Mariani
  • FMFilippo De Marinis
    Filippo De Marinis
  • GPGiovanni Pallotta
    Giovanni Pallotta
  • AAAntonio Antilli
    Antonio Antilli
  • ACAnna Maria Cruciani
    Anna Maria Cruciani
  • MRMassimo Rinaldi
    Massimo Rinaldi

Abstract
Background. Preclinical data suggested that alphainterferon (IFN) may potentiate chemotherapy cytotoxicity. Methods. A prospective multicentric randomized trial was initiated to assess the clinical benefit of adding recombinant alpha‐2‐IFN to combination chemotherapy in patients with metastatic non‐small cell lung cancer. A total of 182 patients were randomized to receive either cisplatin‐epidoxorubicin‐cyclophosphamide (CEP) combination chemotherapy (cisplatin, 60 mg/m2; epidoxorubicin, 50 mg/m2; and cyclophosphamide, 400 mg/m2 intravenously) alone on day 1 or the same chemotherapy plus recombinant alpha‐2‐IFN at the dose of 5 MU intramuscularly from day – 2 to +4, then 3 times weekly. Results. The median survival was 6 months in the CEP plus IFN arm versus 5.5 months in the control arm. The log‐rank test showed a marginal statistically significant difference (P = 0.045) in favor of CEP chemotherapy, which disappeared when survival curves were adjusted for prognostic factors. Progression‐free survival was similar in the two treatment arms. Considering all eligible patients, the response rate was 7.6% in the CEP arm versus 18.9% in the CEP plus IFN arm (P = 0.042). Nearly 40% of the patients receiving IFN had grade 3–4 nadir leukopenia versus 15% in the control arm (P = 0.01) and 12.5% versus 4.2% had grade 3–4 thrombocytopenia. Apart from the usual constitutional symptoms, IFN was also responsible for increased emesis and mucositis. Conclusions. This study indicates that the addition of recombinant alpha‐IFN to CEP chemotherapy can increase response rate and toxicity to treatment without a positive effect on progression‐free survival and survival.

This publication has 16 references indexed in Scilit: